LIMN (Liminatus Pharma) Research & Development: $0.40 Mil (TTM As of Mar. 2026)


What is Liminatus Pharma Research & Development?

Liminatus Pharma LIMN +9.99% Research & Development is $0.40 Mil as of Mar. 2026. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Liminatus Pharma's Research & Development for the three months ended in Mar. 2026 was $0.40 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0.40 Mil.

Liminatus Pharma  (NAS:LIMN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Liminatus Pharma Research & Development Related Terms

Liminatus Pharma Research & Development Historical Data

* Premium members only.

The historical data trend for Liminatus Pharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Liminatus Pharma Research & Development Chart

Liminatus Pharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Research & Development
1.85 3.76 2.69 0.00

Liminatus Pharma Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.40

Liminatus Pharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.40 Mil mean?
Liminatus Pharma (LIMN) has a Research & Development of $0.40 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Liminatus Pharma and its competitors.
Is Liminatus Pharma's Research & Development too high?
Liminatus Pharma's current Research & Development is $0.40 Mil.
How does Liminatus Pharma's Research & Development compare to XBIO and PCSA?
Liminatus Pharma's Research & Development of $0.40 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Liminatus Pharma and its competitors. Liminatus Pharma's current Research & Development is $0.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liminatus Pharma stock overvalued right now?
Liminatus Pharma (LIMN) has a current Research & Development of $0.40 Mil. The current Research & Development is $0.40 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Liminatus Pharma (LIMN), the current Research & Development is $0.40 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Liminatus Pharma Business Description

Address 12611 Hiddencreek Way, Unit C, Cerritos, CA, USA, 90703
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.